Drug products: Aphiahsone, Asmanex HFA, Asmanex® Twisthaler®, Atectura Breezhaler, Demoson, Dulera, Elocom, Elocon®, Enerzair Breezhaler, Momenex, Mometason ABECE, Mometason Apofri, Mometason Glenmark, Mometason Orion, Mometasone Actavis, Mometasone Teva, Mommox, Nasomet, Nasonex, Nasonex®, Orimox, Ovixan
ATC code: D07AC13, R01AD09, R03AK09, R03AK14, R03AL12, R03BA07
Substances: mometasone, mometasone furoate, mometasone furoate monohydrate
Published randomized controlled studies on difference between men and women regarding mometasone efficacy in allergic rhinitis, asthma or dermatological conditions are lacking.
A randomized, double-blind, placebo-controlled study showed that mometasone nasal spray do not inhibit growth in children, neither in boys nor girls.
Mometasone is a corticosteroid used in treatment of allergic rhinitis, asthma and dermatological conditions.
Pharmacokinetics and dosing
The systemic bioavailability of mometasone furoate 400 µg administrated as dry-powder inhaler has been evaluated in healthy volunteers in a randomized, open-label, crossover study (12 men, 12 women). There were no difference in mean absolute bioavailability between men and women (1.04% vs. 0.89%) .
No studies with a clinically relevant sex analysis regarding the effects of mometasone in allergic rhinitis, asthma or dermatologic conditions have been found. The benefit of topical or systemic administration of corticosteroids in patients with olfactory dysfunction was evaluated in a retrospective nonrandomized study (46 men, 46 women). Patients were prescribed either mometasone nasal spray for 1-3 months or oral prednisolone for 21 days (starting dose 40 mg). Mometasone nasal spray did not improve olfactory function, while use of prednisolone led to improvement. Response to therapy was not related to patient’s sex, duration of disease or presence of parosmia dysfunction .
Systemic corticosteroids have been associated with inhibition of growth in children. The effect of mometasone nasal spray on growth in prepubertal children age 3-9 years with allergic rhinitis was evaluated in a randomized, double-blind, placebo-controlled trial (66 boys, 32 girls). In this study, after one year of treatment, mometasone did not retard growth, neither in girls nor in boys .
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2016-09-15
- Affrime MB, Cuss F, Padhi D, Wirth M, Pai S, Clement RP, Lim J, Kantesaria B, Alton K, Cayen MN. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000 Nov;40(11):1227-36 PubMed
- Heilmann S, Huettenbrink KB, Hummel T. Local and systemic administration of corticosteroids in the treatment of olfactory loss. Am J Rhinol. 2004;18:29-33. PubMed
- Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105:E22. PubMed
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-09-15.] Socialstyrelsens statistikdatabas
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson